Sep 26 |
Fulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setback
|
Sep 24 |
Fulcrum reduces its workforce
|
Sep 20 |
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
|
Sep 17 |
RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares
|
Sep 16 |
Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
Sep 13 |
FULC Stock Falls as Muscle Disorder Study Misses Primary Goal
|
Sep 12 |
Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
|
Sep 12 |
Crude Oil Surges 3%; Kroger Posts Upbeat Earnings
|
Sep 12 |
Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial
|
Sep 12 |
Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test
|